VivoSeq
Oncology

Lymphoma, Non-Hodgkin

11

Pipeline Programs↗

9

Active Trials↗

5

Companies Involved↗

Lymphoma, Non-Hodgkin is an emerging landscape with 11 programs across 5 companies. The most active players are Eli Lilly, Dizal Pharmaceuticals, Johnson & Johnson.

Intelligence

Pipeline Metrics

Competitive Density

42/100

Pipeline Velocity

15/100

Mech. Concentration

50/100

Completion Rate

50/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Eli Lilly logo

Eli Lilly

1 program

Phase 1D

Dizal Pharmaceuticals

1 program

Phase 1Johnson & Johnson logo

Johnson & Johnson

6 programs

Phase 1Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

PreclinicalMerck & Co. logo

Merck & Co.

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

70%

Small molecule

7 of 10 classified programs — the dominant modality here.

30%ALL OTHERSMonoclonal antibody220%Cell therapy110%

Small molecule leads; the ring shows all 10 classified programs, each share of the total. Modality classified for 100% of 11 pipeline programs.

Analysis

Trial Status

11

clinical trials

Active, not recruiting5 · 45%
Recruiting3 · 27%
Enrolling by invitation1 · 9%
Completed1 · 9%
Terminated1 · 9%

Clinical Trials

Trial Activity

11 trials

A Phase 1, First-in-Human Study of a Novel CD79bxCD20xCD3 Trispecific Antibody in B-Cell Non-Hodgkin Lymphoid Malignancies (NHLs)
Recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT07308132·130 enrolled
BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies
Recruiting·Eli Lilly logoEli Lilly·Phase 1·NCT07101328·215 enrolled
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma
Recruiting·Merck & Co. logoMerck & Co.·Preclinical·NCT07519772·200 enrolled
A Phase 1, First-in-Human, Dose Escalation Study of JNJ-88998377 in Participants With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma (NHL)
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT06470438·58 enrolled
A Phase 1, First-in-human Study of JNJ-80948543, a T-cell Redirecting Antibody, in Participants With NHL and CLL
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT05424822·167 enrolled
A Phase 1b Study of JNJ-80948543 in Combination With Other CD3 T-Cell Engagers (TCEs) in Participants With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoid (R/R B-Cell NHL) Malignancies
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT06660563·19 enrolled
A Phase 1, First-in-human Study of JNJ-87801493 in Combination With CD3 T-Cell Engagers in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoid Malignancies (NHLs)
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Phase 1·NCT06139406·70 enrolled
A Phase 1b/2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19/CD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma
Active, not recruiting·Johnson & Johnson logoJohnson & Johnson·Preclinical·NCT05421663·166 enrolled
The Lymphoma Epidemiology of Outcomes (LEO) Cohort Study Protocol
Enrolling by invitation·MMayo Clinic·N/A·NCT04996706·21,000 enrolled
A Phase 1, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of DZD8586 in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Completed·DDizal Pharmaceuticals·Phase 1·NCT05824585·17 enrolled
A Phase 1/2 Study of the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adult Participants With Recurrent or Refractory Classical Hodgkin Lymphoma and Non-Hodgkin Lymphoma
Terminated·Bristol-Myers Squibb logoBristol-Myers Squibb·Preclinical·NCT05255601·5 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)